Yahoo
BSE - Delayed Quote INR

Gujarat Themis Biosyn Limited (GUJTHEM.BO)

369.20 +6.70 (+1.85%)
At close: 3:29:17 PM GMT+5:30
Chart Range Bar
Loading chart for GUJTHEM.BO
  • Previous Close 362.50
  • Open 364.70
  • Bid 368.00 x --
  • Ask 373.35 x --
  • Day's Range 362.35 - 380.95
  • 52 Week Range 225.75 - 472.10
  • Volume 8,047
  • Avg. Volume 21,480
  • Market Cap (intraday) 48.052B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) 82.60
  • EPS (TTM) 4.47
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.67 (0.18%)
  • Ex-Dividend Date Sep 23, 2026
  • 1y Target Est --

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

www.gtbl.in

--

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

GUJTHEM.BO
16.42%
S&P BSE SENSEX (^BSESN)
11.18%

1-Year Return

GUJTHEM.BO
20.14%
S&P BSE SENSEX (^BSESN)
9.82%

3-Year Return

GUJTHEM.BO
71.69%
S&P BSE SENSEX (^BSESN)
18.12%

5-Year Return

GUJTHEM.BO
254.81%
S&P BSE SENSEX (^BSESN)
26.09%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY17
Revenue 104.29M
Earnings --
Profit Margin 0.00%

Q4

FY15

Q4

FY17

0
20M
40M
60M
80M
100M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.02%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.74B

  • Net Income Avi to Common (ttm)

    486.87M

  • Diluted EPS (ttm)

    4.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    60.88M

  • Total Debt/Equity (mrq)

    56.23%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: